Coya Therapeutics, Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +246.9% | -9.4% | +6.8% | -11.0% | +24.7% | -13.4% | -12.9% | -4.2% | +55.9% | +6.6% | +88,706.3% | |
| – | +248.5% | -9.4% | +6.8% | -11.0% | +24.8% | -13.4% | -12.9% | -4.2% | +55.9% | +6.7% | +88,250.3% | |
| – | +199.7% | +10.3% | +1.6% | -15.1% | +23.4% | -7.3% | -16.2% | -5.5% | +66.5% | +8.3% | +85,028.3% | |
| – | +199.7% | +10.3% | +1.6% | -15.1% | +23.4% | -7.3% | -16.2% | -5.5% | +66.5% | +8.3% | +85,028.3% | |
| – | – | – | – | – | – | +0.0% | – | – | – | – | – | |
| – | +211.4% | -11.1% | -6.4% | -24.4% | +34.7% | +5.6% | +2.1% | -7.5% | +45.5% | -37.9% | +93,652.9% | |
| – | +179.6% | -14.5% | -11.4% | -39.4% | +64.9% | +13.5% | +3.7% | -18.5% | +60.1% | -39.6% | +98,938.2% | |
| – | – | +0.0% | – | – | – | – | – | – | – | – | – | |
| – | +82.3% | +37.4% | +18.6% | -82.1% | +371.6% | +6.4% | -44.9% | +19.4% | -4.5% | -10.6% | +114,383.0% | |
| – | +253.2% | -9.1% | +8.8% | -9.2% | +23.6% | -15.7% | -15.2% | -3.6% | +57.7% | +13.8% | +88,271.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.2% | +42.2% | +3.2% | +2.1% | +7.5% | +2.2% | +0.0% | +0.0% | 0.0% | +35.3% | +3.6% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.